Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Financing Cash Flow

Financing Cash Flow at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$2.74B+59,591%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
RFL
Rafael Holdings, Inc.RFL
-$28K-355%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
-$10.92M-2,356%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$967K-92.2%
XER
Xeris Biopharma Holdings, Inc.XERS
-$8.84M-182%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$681.73M+6.6%
Enterprise value$537.9M-17.8%
P/E11.7×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 5:14 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001434647-26-000031
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Proceeds from issuance of common stock for options exercised7521,979
Proceeds from issuance of common stock for warrants exercised9,171
Payments of principal on insurance financing arrangements(372)
Net cash (used in) provided by financing activities(52,804)1,607
Effect of exchange rate changes on cash and cash equivalents233(372)
Net increase in cash and cash equivalents33,1893,555
Cash and cash equivalents, beginning of period62,40633,785
Cash and cash equivalents, end of period$95,595$37,340

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s financing cash flow?
Zevra Therapeutics, Inc. (ZVRA) reported financing cash flow of -$52.8M in Q1 2026.
How has Zevra Therapeutics, Inc.'s financing cash flow changed year-over-year?
Zevra Therapeutics, Inc.'s financing cash flow decreased by 3385.9% year-over-year, from $1.61M to -$52.8M.
What is the long-term trend for Zevra Therapeutics, Inc.'s financing cash flow?
Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s financing cash flow has grown at a -53.0% compound annual growth rate (CAGR), from $115.98M to $12.06M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Zevra Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude